https://www.prophecymarketinsights.com/market_insight/China-Precision-Medicine-Market-By-3665

MolDX, short for Molecular Diagnostics Tests, describes a program created by the ⁠ Centers for Medicare & Medicaid Services (CMS) in the United States. By implementing the MolDX program, Medicare aims to offer its ⁠ beneficiaries access to advanced and affordable molecular diagnostic testing. These tests analyse genetic, genomic, and proteomic information at the molecular level, opening opportunities for tailored and precise medical interventions. MolDX evaluates the ⁠ clinical utility and validity of these tests, securing compliance these tests with essential regulatory standards and ensuring they receive suitable reimbursement. By promoting the integration of cutting-edge molecular technologies into clinical practice, enhancing patient results is a key objective for ⁠ MolDX. Moreover, it strives to enhance informed decision-making for healthcare providers and propel the progress of precision medicine. https://securemso.com/10-cpt-code-update-for-molecular-diagnostic-tests/